MedTrace Logo

Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

NCT02977507 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-12-19

Study results available
· View outcomes & findings →

Summary

The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.

Conditions

  • Melasma

Interventions

OTHER

Lytera 2.0

Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.

DRUG

4% Hydroquinone Topical Cream

4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.

OTHER

SkinMedica Facial Cleanser

SkinMedica facial cleanser applied to the face as directed.

OTHER

SkinMedica Rejuvenative Moisturizer

SkinMedica rejuvenative moisturizer applied to the face as directed.

OTHER

SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen

SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Elizabeth Makino · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-13
Primary Completion
2017-10-09
Completion
2017-10-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02977507 on ClinicalTrials.gov